DengyueMed Report: China's National Medical Products Administration has approved a milestone antitumor new drug—Bezean (Tislelizumab Injection)—for the treatment of various advanced solid tumors, including non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), and hepatocellu...